Oncolytics Biotech® Collaborators to Present Reovirus Research at the 14th World Conference on Lung Cancer
Complete the form below to unlock access to ALL audio articles.
Oncolytics Biotech Inc., has announced that an abstract covering interim preliminary results from a Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumours is available on the International Association for the Study of Lung Cancer World Conference on Lung Cancer website at http://www.2011worldlungcancer.org/index.html.
The conference is being held in Amsterdam, the Netherlands from July 3rd - 7th 2011.
The abstract, entitled "Phase II study of reovirus with paclitaxel (P) and carboplatin (C) in patients with metastatic non-small cell lung cancer (NSCLC) who have Kras or EGFR-activated tumors", authored by Villalona-Calero et al, indicated that as of the date of submission of the abstract 21 patients had received Reovirus (REOLYSIN) (3 x 1010 TCID50) intravenously daily on days one to five, in combination with carboplatin and paclitaxel.
Initial doses used were carboplatin AUC 6 on day one, and palitaxel 200 mg/m2, on day one of each 21-day cycle. Due to exacerbation of prior gastrointestinal conditions and febrile neutropenia (one each) in first two patients, doses were reduced to paclitaxel 175 mg/m m2 and carboplatin AUC 5.
Overall, 85 cycles (per patient median four, range one to eight) were administered. Grade 3-4 adverse events included grade 4 neutropenia (four patients), anemia, fatigue, electrolyte abnormalities, diarrhea, (two patients), and single cases of nausea, vomiting, and sepsis.
Molecular tumor demographics included: eight Kras mutant, three EGFR mutant, 15 EGFR amplified.
Response evaluation to date in 20 patients showed six partial responses (PR) (30%), 12 stable disease (SD)(60%), two progressive disease (PD)(10%). This translates into a clinical benefit rate (complete response (CR)+PR+SD) of 90% and a response rate (CR+PR) of 30%.
"Although preliminary, this data is very encouraging. Once we have data from our ongoing Phase II trial in squamous cell carcinoma lung cancer, we will decide which lung cancer indication will proceed into a randomized clinical study," said Dr. Brad Thompson, President and CEO of Oncolytics.
